Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxe...
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)
About this item
Full title
Author / Creator
van der Noll, Ruud , Jager, Agnes , Ang, Joo Ern , Marchetti, Serena , Mergui-Roelvink, Marja W. J. , Lolkema, Martijn P. , de Jonge, Maja J. A. , van der Biessen, Diane A. , Brunetto, Andre T. , Arkenau, Hendrik-Tobias , Tchakov, Ilian , Beijnen, Jos H. , de Bono, Johann S. and Schellens, Jan H. M.
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Summary
Background
The PARP inhibitor olaparib has shown acceptable toxicity at doses of up to 400 mg twice daily (bid; capsule formulation) with encouraging signs of antitumor activity. Based on its mode of action, olaparib may sensitize tumor cells to DNA-damaging agents. This Phase I trial (NCT00516724) evaluated the safety, pharmacokineti...
Alternative Titles
Full title
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2420902034
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2420902034
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1007/s10637-019-00856-7
